Video

Dr. Steven Coutre on Frontline Treatment Decisions in CLL

​Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).

Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).

When determining frontline treatment, it is important to consider each patient’s individual needs, and not just make a medical-based decision, says Coutre.

A frail patient or a patient with multiple comorbidities may not be able to tolerate a chemoimmunotherapy regimen, and should therefore be given an oral regimen.

Financial constraints may also need to be a considered for some patients. A defined course of therapy like chemoimmunotherapy may be fully reimbursed by insurance, while a long-term oral therapy may not be, says Coutre.

<<<

View more from the 2016 NCCN Hematologic Malignancies Congress

Related Videos
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec